1218918-75-2Relevant articles and documents
Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases
Gallant, Michel,Beaulieu, Christian,Berthelette, Carl,Colucci, John,Crackower, Michael A.,Dalton, Chad,Denis, Danielle,Ducharme, Yves,Friesen, Richard W.,Guay, Daniel,Gervais, Franois G.,Hamel, Martine,Houle, Robert,Krawczyk, Connie M.,Kosjek, Birgit,Lau, Stephen,Leblanc, Yves,Lee, Ernest E.,Levesque, Jean-Franois,Mellon, Christophe,Molinaro, Carmela,Mullet, Wayne,O'Neill, Gary P.,O'Shea, Paul,Sawyer, Nicole,Sillaots, Susan,Simard, Daniel,Slipetz, Deborah,Stocco, Rino,S?rensen, Dan,Truong, Vouy Linh,Wong, Elizabeth,Wu, Jin,Zaghdane, Helmi,Wang, Zhaoyin
scheme or table, p. 288 - 293 (2011/02/27)
In this manuscript we wish to report the discovery of MK-7246 (4), a potent and selective CRTH2 (DP2) antagonist. SAR studies leading to MK-7246 along with two synthetic sequences enabling the preparation of this novel class of CRTH2 antagonist are reported. Finally, the pharmacokinetic and metabolic profile of MK-7246 is disclosed.
